It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Inhaled administration of polymyxin B is increasingly used to treat multi-drug resistant bacterial lung infections. However, the lack of clinical data on the pharmacokinetics of inhaled administration makes drug dose design, efficacy assessment and drug safety assessment a challenge. In this study, clinical data from intravenous injections were deconvoluted by an equal-step numerical deconvolution algorithm to derive the drug absorption rate of polymyxin B in vivo. The absorption rate was substituted into a published pulmonary absorption compartment model to predict the systemic pharmacokinetics of polymyxin B. It was demonstrated that the intravenous PK dataset with the pulmonary compartment model provided reliable estimates of the accuracy and bias of inhaled systemic pharmacokinetics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer